Taipale, Heidi
Lähteenvuo, Markku
Tanskanen, Antti
Huoponen, Saara
Rannanpää, Saara
Tiihonen, Jari
Funding for this research was provided by:
Janssen Cilag
Karolinska Institute
Article History
Received: 30 December 2021
Accepted: 5 July 2022
First Online: 19 July 2022
Declarations
:
: The research project was approved by pertinent institutional authorities at the Finnish National Institute for Health and Welfare (permission 635/5.05.00/2019), the Social Insurance Institution of Finland (31/522/2019), Finnish Centre for Pensions (19023) and Statistics Finland (TK-53-569-19). Informed consent was not sought due to the registry-based nature of the study as data. According to Finnish legislation, no informed consent is required when administrative data in governmental registers already being collected is used and data is anonymized so no specific individual could be identified (the Act on the secondary use of health and social data). Study persons were not contacted and no experiments for them were made. Only researchers who were granted with administrative permission from National Institute of Health and Welfare, Social Insurance Institution and Finnish Centre of Pensions had access to raw data. All methods were carried out in accordance with Declaration of Helsinki.
: Not applicable.
: JT, HT and AT have participated in research projects funded by grants from Janssen Cilag and Eli Lilly to their employing institution. HT reports personal fees from Janssen Cilag and Otsuka. JT reports personal fees from Eli Lilly, Janssen Cilag, Lundbeck, and Otsuka; is a member of advisory board for Lundbeck. ML is a board member of Genomi Solutions ltd. and Nursie Health ltd., has received honoraria from Sunovion ltd., Orion Pharma ltd., Lunbdbeck ltd., Otsuka Pharma ltd., and Janssen Cilag and research funding from Janssen Cilag, the Finnish Medical Foundation, the Finnish Cultural Foundation and the Emil Aaltonen Foundation. SR and SH are employees of Janssen Cilag.